Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golixitinib plus chidamide in previously systemically treated cutaneous T-cell lymphoma (Phase I/II)
ChiCTR2600120648Phase 2Recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golixitinib and tucidinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Overall response rate. Started Mar 2026; status: recruiting.
02
Drugs
golixitinibtucidinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on ChiCTR2600120648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120648.